Healthcare Industry News:  Optimer Pharmaceuticals 

Biopharmaceuticals Personnel

 News Release - June 14, 2006

Optimer Pharmaceuticals Names John D. Prunty Chief Financial Officer

SAN DIEGO--(HSMN NewsFeed)--June 14, 2006--Optimer Pharmaceuticals, Inc. has appointed John D. Prunty, C.P.A., as the company's Chief Financial Officer and Vice President of Finance.

"We are very fortunate to have someone of John's caliber joining Optimer," said Michael N. Chang, CEO and President of Optimer. "With his strong finance and accounting background, he is a great addition to the Optimer team."

John Prunty joins Optimer with over 20 years of senior management experience in finance, accounting, public offerings, mergers and acquisitions, and SEC accounting and reporting. Prior to joining Optimer, he was the Chief Financial Officer, Vice President of Finance, and the Corporate Secretary at Maxim Pharmaceuticals, Inc., where he served for over five years as a finance executive. He also served as Senior Director of Finance and the Corporate Controller for Gen-Probe Incorporated and held senior level finance positions at I-Bus, a Division of Maxwell Technologies. John began his career as an auditor at Ernst & Young, LLP, where he spent seven years in public accounting. He is a certified public accountant and received a B.B.A. from the University of San Diego and a M.S. in Management from San Diego State University.

Optimer Pharmaceuticals, Inc., a privately held biopharmaceutical company based in San Diego, CA, is focused on the development and global commercialization of anti-infective products for the treatment of serious infections. The Company also specializes in using its proprietary synthetic glycol-chemistry technology for drug discovery. More information can be found at

Source: Optimer Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.